Seminars

 

Pharmacokinetics (PK)/Toxicokinetics (TK)

Using Gyrolab xP system to meet tight deadlines

Shawn Fernando, Senior Researcher, Bioanalytical Development, Morphotek, Exton, PA, USA, presented ‘Development and Validation of a Pharmacokinetic Assay on the Gyrolab Platform for Use in Phase II/III Clinical Trials’ at the North American Gyrolab Seminar, 2012, USA.
View Seminar

Developing fit for purpose assays using the Gyrolab platform

Sabrina Lory, Head of the Bioanalytical Assay Laboratory, NovImmune, presented ‘Developing fit for purpose assays using the Gyrolab platform’, at the 2012 International Gyrolab Seminar.
View Seminar

Gyrolab xP workstation speeds up ADC assay development and throughput

Annette Wu in the PDM group at Pfizer, La Jolla, CA, USA, presented ‘Case study: Antibody-drug conjugates TK study on Gyros immunoassay platform’ at the Gyrolab Seminar, 2011, USA.
View Seminar

 

Pharmacodynamics (PD) & Biomarker monitoring

Developing fit for purpose assays using the Gyrolab platform

Sabrina Lory, Head of the Bioanalytical Assay Laboratory, NovImmune, presented ‘Developing fit for purpose assays using the Gyrolab platform’, at the 2012 International Gyrolab Seminar.
View Seminar

Glucagon-Like Peptide 1 Quantitation: Gyros vs Other Detection Platforms

Mark Dysinger, Senior Scientist, Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, USA. Presentation at the 2nd Annual North American Gyrolab Seminar, 2011, USA.
View Seminar

Performance of the Gyrolab xP system for custom development of preclinical urinary renal biomarker assays

Diane Hamlin, Investigative Toxicology, Eli Lilly and Company. Presentation at the International Gyrolab Seminar, ‘Changing the Immunoassay Landscape using Automated Nanoliter-scale Innovation’, October 3-4, 2012, USA.
View Seminar

 

Immunogenicity

Developing fit for purpose assays using the Gyrolab platform

Sabrina Lory, Head of the Bioanalytical Assay Laboratory, NovImmune, presented ‘Developing fit for purpose assays using the Gyrolab platform’, at the 2012 International Gyrolab Seminar.
View Seminar

 

Impurity testing

The automation of a high throughput residual HCP assay to support in-process analysis of monoclonal antibodies

Jun Heo, Analytical Biochemist, Biologics-New and Enabling Technologies, Merck & Co Inc. Presentation at the International Gyrolab Seminar, ‘Changing the Immunoassay Landscape using Automated Nanoliter-scale Innovation’, October 3-4, 2012, USA.
View Seminar

The value of Gyrolab xP workstation in HCP analysis and bioprocess

Daniel Schiwek,Project Evaluation Manager at Global Biological Operations, Lonza AG,Visp, Switzerland, presented ‘Biopharmaceutical manufacturing in microbial systems – Gyrolab™ as an analytical platform supporting process development’ at the Gyrolab Seminar, 2011, held in Siena, Italy.
View Seminar